U.S.P.S. EXPRESS MAIL "POST OFFICE TO ADDRESSEE" SERVICE **DEPOSIT INFORMATION**

Express Mail Label No.:	EV 325989907 US
·	

Date of Deposit: ____July 12, 2004

В	RI	N	K	S
Н	0	F	E	R
G	۱L	S	0	N
&	LI	0	N	Ε

Examiner: Nancy T. Vogel

Art Unit: 1636

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: Baker, et al.

Appln. No.:

09/944,929

Filed:

August 31, 2001

For:

SECRETED AND TRANSMEMBRANE

POLYPEPTIDES AND NUCLEIC ACIDS

ENCODING THE SAME

Attorney Docket No:

10466/140-1 (P2548P1C21)

Mail Stop RCE **Commissioner for Patents** U.S. Patent and Trademark Office P. O. Box 1450 Alexandria, VA 22313-1450

REQUEST FOR CONTINUED EXAMINATION (37 C.F.R. § 1.114)

Sir:

tion of the above identified application under 37

C.F.	Ар R. §1.	•	it(s) requests continued examination of the above-identified application drider or		
\boxtimes	Submission under 37 CFR 1.114 (check at least one of the following):				
		Prev	riously submitted:		
			Applicant(s) requests nonentry of any previously-filed unentered amendments.		
			Please enter and consider the Amendment After Final Under 37 C.F.R. §1.116 previously filed on		
			Consider the arguments in the Appeal Brief or Reply Brief previously filed on		
			Other:		
	\boxtimes	Atta	ched is/are:		
			An Information Disclosure Statement		
			An Amendment to the written description, claims, or drawings		
		\boxtimes	New Arguments and/or New Evidence in support of Patentability		
			Other:		

770.00 OP

00000138 09944929 07/15/2004 HRL111 01 FC:1801 Appln. No. <u>09/944,929</u>

	Request for suspension of action:		
	37 C	licant(s) hereby request suspension of act C.F.R. §1.103(c) for a period of more onths; requires Processing Fee under 37 (tion on the above-identified application under nths. (Period of suspension shall not exceed C.F.R. §1.17(i)).
☐ Small Entity Status:			
		Applicant hereby asserts entitlement t §§ 1.9 and 1.27.	o claim small entity status under 37 CFR
			entitlement to claim small entity status was and such status is still proper and desired.
		Is no longer desired.	
\boxtimes	Applicant(s) calculate the following fees to be due in connection with this Request:		due in connection with this Request:
	\boxtimes	A Request fee of \$770.00 under 37 C.F.	R. §1.17(e).
		A suspension processing fee of \$	under 37 C.F.R. §1.17(i).
		An additional filing fee of \$ undependent claims and/or addition	under 37 C.F.R. §1.16 (additional onal total claims).
	\boxtimes	An extension fee of \$420.00 under 37 time.	C.F.R. §1.17(a) for a 2-month extension of
\boxtimes	Fee	payment to cover the above-enumerated	fee(s):
	\boxtimes	A check in the amount of \$1,190.00 is en	nclosed.
		Please charge Deposit Account No. 23-the amount of \$ A copy of this Re	1925 (BRINKS HOFER GILSON & LIONE) in equest is enclosed for this purpose.
		A payment by credit card in the amount	of \$ (Form PTO-2038 is attached).
		fees required under 37 CFR § 1.16 and 37 CFR § 1.17 associated with this pa ensure that this paper is timely filed),	d to charge payment of any additional filing any patent application processing fees under per (including any extension fee required to or to credit any overpayment, to Deposit GILSON & LIONE). A copy of this Request
		F	Respectfully submitted,
12 Date	Jul	Ly 2004	Noel Kaman (Reg. No. 51,857)
Atta	chmer		

U.S.P.S. EXPRESS MAIL "POST OFFICE TO ADDRESSEE" SERVICE DEPOSIT INFORMATION

Express Mail Label No.: EV 325989907 US

Date of Deposit: ____July 12, 2004

JUL 1 2 2004 3

Our Case No. 10466/140 P2584P1C21

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Kevin P. Baker et al.)
Serial No.: 09/944,929) Examiner: Nancy T. Vogel)
Filing Date: August 31, 2001) Group Art Unit No.: 1636)
For: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME))

AMENDMENT AND REQUEST FOR CONTINUED EXAMINATION

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action mailed February 12, 2004, the Applicants respectfully request continued examination in light of the following remarks.

Remarks begin on page 2 of this paper.